TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GlaxoSmithKline is paying iTeos Therapeutics $625 million up front to share in the development of an antibody that targets the TIGIT protein, a hot target in cancer immunotherapy R&D.

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, ... GSK said that the drug could be used alongside other drugs being developed for MASH, including GLP-1 agonists.

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

iTeos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am rating RCUS stock a Hold for now.

When added to GSK’s drug Jemperli, the immunotherapy, known as belrestotug and aimed at a cellular target called TIGIT, didn’t meet preset criteria for progression-free survival compared to ...

Today's biotech news roundup includes thoughts on hopes for TIGIT and questions about Summit Therapeutics' ivonescimab data in lung cancer.

Their lead product, EOS-448 (or belrestotug), is an antagonist of TIGIT, with a recent collaboration with GlaxoSmithKline to further its development. Another notable candidate, inupadenant ...

Merck & Co.'s TIGIT therapy tacked on to Keytruda did not improve progression-free survival in a phase 2 lung cancer trial, marking the latest failure for the class. The company reported open ...